167 related articles for article (PubMed ID: 37674626)
1. Endogenous H3.3K27M derived peptide restricted to HLA-A∗02:01 is insufficient for immune-targeting in diffuse midline glioma.
Wang SS; Pandey K; Watson KA; Abbott RC; Mifsud NA; Gracey FM; Ramarathinam SH; Cross RS; Purcell AW; Jenkins MR
Mol Ther Oncolytics; 2023 Sep; 30():167-180. PubMed ID: 37674626
[TBL] [Abstract][Full Text] [Related]
2. H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2
Immisch L; Papafotiou G; Popp O; Mertins P; Blankenstein T; Willimsky G
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302563
[TBL] [Abstract][Full Text] [Related]
3. A novel mouse model of diffuse midline glioma initiated in neonatal oligodendrocyte progenitor cells highlights cell-of-origin dependent effects of H3K27M.
Tomita Y; Shimazu Y; Somasundaram A; Tanaka Y; Takata N; Ishi Y; Gadd S; Hashizume R; Angione A; Pinero G; Hambardzumyan D; Brat DJ; Hoeman CM; Becher OJ
Glia; 2022 Sep; 70(9):1681-1698. PubMed ID: 35524725
[TBL] [Abstract][Full Text] [Related]
4. H3F3A K27M Mutations Drives a Repressive Transcriptome by Modulating Chromatin Accessibility, Independent of H3K27me3 in Diffuse Midline Glioma.
Bhattarai S; Hakkim FL; Day CA; Grigore F; Langfald A; Entin I; Hinchcliffe EH; Robinson JP
bioRxiv; 2024 May; ():. PubMed ID: 38798502
[TBL] [Abstract][Full Text] [Related]
5. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.
Mueller S; Taitt JM; Villanueva-Meyer JE; Bonner ER; Nejo T; Lulla RR; Goldman S; Banerjee A; Chi SN; Whipple NS; Crawford JR; Gauvain K; Nazemi KJ; Watchmaker PB; Almeida ND; Okada K; Salazar AM; Gilbert RD; Nazarian J; Molinaro AM; Butterfield LH; Prados MD; Okada H
J Clin Invest; 2020 Dec; 130(12):6325-6337. PubMed ID: 32817593
[TBL] [Abstract][Full Text] [Related]
6. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M
Mount CW; Majzner RG; Sundaresh S; Arnold EP; Kadapakkam M; Haile S; Labanieh L; Hulleman E; Woo PJ; Rietberg SP; Vogel H; Monje M; Mackall CL
Nat Med; 2018 May; 24(5):572-579. PubMed ID: 29662203
[TBL] [Abstract][Full Text] [Related]
7. Cooperativity between H3.3K27M and PDGFRA poses multiple therapeutic vulnerabilities in human iPSC-derived diffuse midline glioma avatars.
Skinner KR; Koga T; Miki S; Gruener RF; Grigore FN; Torii EH; Seelig DM; Suzuki Y; Kawauchi D; Lin B; Malicki DM; Chen CC; Benveniste EN; Patel RP; McFarland BC; Huang RS; Jones C; Mackay A; Miller CR; Furnari FB
bioRxiv; 2023 Feb; ():. PubMed ID: 36865329
[TBL] [Abstract][Full Text] [Related]
8. Histone H3.3 K27M chromatin functions implicate a network of neurodevelopmental factors including ASCL1 and NEUROD1 in DIPG.
Lewis NA; Klein RH; Kelly C; Yee J; Knoepfler PS
Epigenetics Chromatin; 2022 May; 15(1):18. PubMed ID: 35590427
[TBL] [Abstract][Full Text] [Related]
9. Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR.
Li D; Bonner ER; Wierzbicki K; Panditharatna E; Huang T; Lulla R; Mueller S; Koschmann C; Nazarian J; Saratsis AM
Sci Rep; 2021 Mar; 11(1):5098. PubMed ID: 33658570
[TBL] [Abstract][Full Text] [Related]
10. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.
Chheda ZS; Kohanbash G; Okada K; Jahan N; Sidney J; Pecoraro M; Yang X; Carrera DA; Downey KM; Shrivastav S; Liu S; Lin Y; Lagisetti C; Chuntova P; Watchmaker PB; Mueller S; Pollack IF; Rajalingam R; Carcaboso AM; Mann M; Sette A; Garcia KC; Hou Y; Okada H
J Exp Med; 2018 Jan; 215(1):141-157. PubMed ID: 29203539
[TBL] [Abstract][Full Text] [Related]
11. INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas.
Grassl N; Sahm K; Süße H; Poschke I; Bunse L; Bunse T; Boschert T; Mildenberger I; Rupp AK; Ewinger MP; Lanz LM; Denk M; Tabatabai G; Ronellenfitsch MW; Herrlinger U; Glas M; Krex D; Vajkoczy P; Wick A; Harting I; Sahm F; von Deimling A; Bendszus M; Wick W; Platten M
Neurol Res Pract; 2023 Oct; 5(1):55. PubMed ID: 37853454
[TBL] [Abstract][Full Text] [Related]
12. A Novel Peptide-MHC Targeted Chimeric Antigen Receptor T Cell Forms a T Cell-like Immune Synapse.
Wang SS; Luong K; Gracey FM; Jabar S; McColl B; Cross RS; Jenkins MR
Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944696
[TBL] [Abstract][Full Text] [Related]
13. Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review.
Hashii Y; Oka Y; Kagawa N; Hashimoto N; Saitou H; Fukuya S; Kanegae M; Ikejima S; Oji Y; Ozono K; Tsuboi A; Sugiyama H
Front Oncol; 2020; 10():1188. PubMed ID: 32793489
[TBL] [Abstract][Full Text] [Related]
14. HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma.
Wang SS; Davenport AJ; Iliopoulos M; Hughes-Parry HE; Watson KA; Arcucci V; Mulazzani M; Eisenstat DD; Hansford JR; Cross RS; Jenkins MR
Neurooncol Adv; 2023; 5(1):vdad024. PubMed ID: 37152812
[TBL] [Abstract][Full Text] [Related]
15. Targeting the reprogrammed metabolism in H3.3K27M pediatric high-grade gliomas.
de Camargo Magalhães ES; de Bont ESJM; Bruggeman SWM; Lima FRS
Biochim Biophys Acta Mol Basis Dis; 2024 May; 1870(6):167248. PubMed ID: 38777100
[TBL] [Abstract][Full Text] [Related]
16. H3.3K27M Mutation Controls Cell Growth and Resistance to Therapies in Pediatric Glioma Cell Lines.
Rakotomalala A; Bailleul Q; Savary C; Arcicasa M; Hamadou M; Huchedé P; Hochart A; Restouin A; Castellano R; Collette Y; Dieny E; Vincent A; Angrand PO; Le Bourhis X; Leblond P; Furlan A; Castets M; Pasquier E; Meignan S
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771714
[TBL] [Abstract][Full Text] [Related]
17. Epigenome Programming by H3.3K27M Mutation Creates a Dependence of Pediatric Glioma on SMARCA4.
Mo Y; Duan S; Zhang X; Hua X; Zhou H; Wei HJ; Watanabe J; McQuillan N; Su Z; Gu W; Wu CC; Vakoc CR; Hashizume R; Chang K; Zhang Z
Cancer Discov; 2022 Dec; 12(12):2906-2929. PubMed ID: 36305747
[TBL] [Abstract][Full Text] [Related]
18. Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma.
Deng H; Zeng J; Zhang T; Gong L; Zhang H; Cheung E; Jones C; Li G
Mol Cancer Res; 2018 Apr; 16(4):623-633. PubMed ID: 29453317
[TBL] [Abstract][Full Text] [Related]
19. Histone H3.3K27M Represses
Cordero FJ; Huang Z; Grenier C; He X; Hu G; McLendon RE; Murphy SK; Hashizume R; Becher OJ
Mol Cancer Res; 2017 Sep; 15(9):1243-1254. PubMed ID: 28522693
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotide therapy for H3.3K27M diffuse midline glioma.
Zhang Q; Yang L; Liu YH; Wilkinson JE; Krainer AR
Sci Transl Med; 2023 Apr; 15(691):eadd8280. PubMed ID: 37043556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
